Evotec Subsidiary Secures up to $10 Million BARDA Award for Ebola Antibody Manufacturing
Just - Evotec Biologics won a multi-year BARDA award worth up to $10 million to optimize production of a monoclonal antibody cocktail targeting Ebola and Sudan viruses. The program will apply its AI-driven biomanufacturing platform to develop high-yield, scalable, cost-efficient processes for two survivor-derived antibodies, enhancing U.S. outbreak response capabilities.
1. BARDA Award Details
The agreement includes a base period and two option periods, with total potential funding of up to $10 million. Funding will support process development and scale-up activities for a monoclonal antibody cocktail against Ebola virus (EBOV) and Sudan virus (SUDV).
2. Biomanufacturing Platform Capabilities
Just - Evotec Biologics will leverage its AI/ML-driven platform for molecular optimization, cell line development, and process intensification. The goal is to establish robust, high-yield manufacturing workflows that reduce costs and accelerate production timelines.
3. Program Goals and Public Health Impact
The project will convert survivor-derived antibodies from the 2014 Ebola outbreak into scalable, cost-efficient processes. Enhanced manufacturing robustness and speed aim to bolster national preparedness for hemorrhagic fever outbreaks.